Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 3/20 | 0.39 |
| ▸ | CA7 | P43166 | 3/20 | 0.39 |
| ▸ | CA9 | Q16790 | 3/20 | 0.39 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.38 |
| ▸ | ADH1B | P00325 | 1/20 | 0.36 |
| ▸ | ADH1C | P00326 | 1/20 | 0.36 |
| ▸ | ADH1A | P07327 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | GRIA1 | P42261 | 3/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12988956 | 0.82 | GRIA4 (0.42) | CA12CA7CA9CA14ALDH1A1 | |
| SCHEMBL8909346 | 0.81 | GRIA1 (0.41) | CA12CA7CA9CA14ALDH1A1 | |
| SCHEMBL10510598 | 0.79 | TSHR (0.36) | GRIA4GRIA1TSHR | |
| SCHEMBL9114458 | 0.79 | GRIA4 (0.36) | GRIA4GRIA1 | |
| SCHEMBL12194930 | 0.79 | RELA (0.39) | CA12CA7CA9CA14ALDH1A1 | |
| SCHEMBL14011294 | 0.77 | CA12 (0.36) | CA12CA7CA9CA14ALDH1A1 | |
| SCHEMBL19996799 | 0.77 | CA12 (0.36) | CA12CA7CA9CA14ALDH1A1 | |
| SCHEMBL9660903 | 0.77 | RELA (0.45) | CA12CA7CA14CA1CA2 | |
| SCHEMBL17149388 | 0.76 | GRIA4 (0.37) | GRIA4CA1MEN1KMT2ACA2 | |
| SCHEMBL23905111 | 0.75 | RELA (0.47) | CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2694505-B1 | HSP90 INHIBITORS | SLOAN KETTERING INST CANCER RES (US) | 2022-04-27 | — | — | EP | claimed |
| US-10201623-B2 | HSP90-targeted cardiac imaging and therapy | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2019-02-12 | — | — | US | claimed |
| US-20160264577-A1 | HSP90 INHIBITORS | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 2016-09-15 | — | — | US | claimed |
| US-20140088121-A1 | HSP90 Inhibitors | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2014-03-27 | — | — | US | claimed |
| US-12616759-B2 | Uses of labeled HSP90 inhibitors | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2026-05-05 | — | — | US | disclosed |
| US-11976075-B2 | Inhibitors of the MYST family of lysine acetyl transferases | Isosterix, Inc. | 2024-05-07 | — | — | US | disclosed |
| US-11976075-B2 | Inhibitors of the MYST family of lysine acetyl transferases | Isosterix, Inc. | 2024-05-07 | — | — | US | disclosed |
| US-20240058482-A1 | USES OF LABELED HSP90 INHIBITORS | SLOAN KETTERING INST CANCER RES (US) | 2024-02-22 | — | — | US | disclosed |
| US-20230303580-A1 | INHIBITORS OF THE MYST FAMILY OF LYSINE ACETYL TRANSFERASES | Isosterix, Inc. | 2023-09-28 | — | — | US | disclosed |
| US-20230303580-A1 | INHIBITORS OF THE MYST FAMILY OF LYSINE ACETYL TRANSFERASES | Isosterix, Inc. | 2023-09-28 | — | — | US | disclosed |
| WO-2023147597-A2 | ALLOSTERIC STING MODULATORS AND METHODS OF USE | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2023-08-03 | — | — | WO | disclosed |
| US-11607465-B2 | Uses of labeled HSP90 inhibitors | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2023-03-21 | — | — | US | disclosed |
| US-20120071514-A1 | BENZOXAZOLONE DERIVATIVES AS ALDOSTERONE SYNTHASE INHIBITORS | NOVARTIS AG (CH) | 2012-03-22 | — | — | US | disclosed |
| US-20120071514-A1 | BENZOXAZOLONE DERIVATIVES AS ALDOSTERONE SYNTHASE INHIBITORS | NOVARTIS AG (CH) | 2012-03-22 | — | — | US | disclosed |
| US-20110166116-A1 | NEW COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS RELATING THERETO | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-07-07 | — | — | US | disclosed |
| US-20110166116-A1 | NEW COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS RELATING THERETO | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-07-07 | — | — | US | disclosed |
| US-20090131436-A1 | Pyrimidine Derivatives | NOVARTIS AG (CH) | 2009-05-21 | — | — | US | disclosed |
| US-7449447-B2 | Peptidomimetic NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION (US) | 2008-11-11 | — | — | US | disclosed |
| US-20070203183-A1 | Diaryl piperidines as CB1 modulators | SCHERING CORPORATION | 2007-08-30 | — | — | US | disclosed |
| US-20070203183-A1 | Diaryl piperidines as CB1 modulators | SCHERING CORPORATION | 2007-08-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070203183-A1 | Diaryl piperidines as CB1 modulators | CNR1, CNR2, GPR119 | CA12 4446/4885CA7 3932/4885CA9 3551/4885 |
| US-20140088121-A1 | HSP90 Inhibitors | HSP90AB1, HSP90B1, HSP90AB2P | CA12 2723/4885CA7 2409/4885CA9 1478/4885 |
| US-20240058482-A1 | USES OF LABELED HSP90 INHIBITORS | HSP90AB1, HSP90B1, HSP90AA1 | CA12 4245/4885CA7 4448/4885CA9 4186/4885 |
| US-20160264577-A1 | HSP90 INHIBITORS | HSP90AB1, HSP90B1, HSP90AB2P | CA12 2719/4885CA7 2391/4885CA9 1461/4885 |
| US-20230303580-A1 | INHIBITORS OF THE MYST FAMILY OF LYSINE ACETYL TRANSFERASES | KAT6A, KAT6B, KAT2A | CA12 4272/4885CA7 3349/4885CA9 3963/4885 |
| US-12616759-B2 | Uses of labeled HSP90 inhibitors | HSP90AB1, HSP90B1, HSP90AB2P | CA12 4053/4885CA7 4182/4885CA9 3580/4885 |
| US-10201623-B2 | HSP90-targeted cardiac imaging and therapy | HSP90AB1, HSP90AA1, HSP90B1 | CA12 2081/4885CA7 2981/4885CA9 2217/4885 |
| US-11976075-B2 | Inhibitors of the MYST family of lysine acetyl transferases | KAT6A, KAT6B, KAT2A | CA12 4272/4885CA7 3349/4885CA9 3963/4885 |
| US-20120071514-A1 | BENZOXAZOLONE DERIVATIVES AS ALDOSTERONE SYNTHASE INHIBITORS | CYP11B2, CYP11B1, CYP21A2 | CA12 2651/4885CA7 759/4885CA9 924/4885 |
| US-20110166116-A1 | NEW COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS RELATING THERETO | MC2R, REN, CYP11B2 | CA12 2572/4885CA7 1513/4885CA9 1655/4885 |
| US-11607465-B2 | Uses of labeled HSP90 inhibitors | HSP90AB1, HSP90B1, HSP90AA1 | CA12 4245/4885CA7 4448/4885CA9 4186/4885 |
| US-20090131436-A1 | Pyrimidine Derivatives | DPYD, TYMP, TYMS | CA12 4835/4885CA7 4573/4885CA9 4296/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.